论文部分内容阅读
目的观察通心络胶囊联合阿托伐他汀钙片治疗冠心病合并高脂血症的临床效果。方法选择2013年9月—2015年1月收治的冠心病合并高脂血症患者162例作为研究对象,随机分为对照组和治疗组各81例。对照组采用阿托伐他汀钙片治疗,治疗组在对照组的基础上联合通心络胶囊治疗,两组均治疗2个疗程。比较两组治疗前后血脂水平、心电图疗效、总体疗效。计量资料组间比较采用t检验,组内比较采用配对t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗后,治疗组与对照组TG、TC及LDL-C水平分别为(1.62±0.26)、(4.03±0.67)、(2.73±0.36)、(1.72±0.23)、(4.38±0.72)、(3.12±0.37)mmol/L,HDL-C水平分别为(1.24±0.34)、(1.08±0.26)mmol/L,与治疗前的(1.91±0.32)、(6.02±0.82)、(0.79±0.31)、(4.49±0.29)、(1.89±0.37)、(5.95±0.78)、(0.75±0.22)、(4.56±0.46)mmol/L比较差异均有统计学意义(均P<0.05)。治疗后两组间各指标比较差异均有统计学意义(均P<0.05)。治疗组心电图总有效率为88.89%,显著高于对照组的72.84%,差异有统计学意义(P<0.05)。治疗组总有效率为92.59%,高于对照组的76.54%,差异有统计学意义(P<0.05)。结论通心络胶囊联合阿托伐他汀钙片治疗冠心病合并高脂血症临床效果显著,值得临床推广。
Objective To observe the clinical effect of Tongxinluo capsule combined with atorvastatin calcium tablets in the treatment of coronary heart disease complicated with hyperlipidemia. Methods 162 patients with coronary heart disease complicated with hyperlipidemia admitted from September 2013 to January 2015 were selected as the research object and randomly divided into control group and treatment group with 81 cases each. The control group was treated with atorvastatin calcium, the treatment group was treated with Tongxinluo capsule on the basis of the control group, and both groups were treated with 2 courses of treatment. Before and after treatment, blood lipid levels, electrocardiogram efficacy and overall curative effect were compared. Measurement data were compared between groups using t test, the group was compared using paired t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, the levels of TG, TC and LDL-C in the treatment group and the control group were (1.62 ± 0.26), (4.03 ± 0.67), (2.73 ± 0.36), (1.72 ± 0.23) and (4.38 ± 0.72) 3.12 ± 0.37 mmol / L and HDL-C levels were 1.24 ± 0.34 and 1.08 ± 0.26 mmol / L respectively, which were significantly higher than those before treatment (1.91 ± 0.32, 6.02 ± 0.82, 0.79 ± 0.31, , (4.49 ± 0.29), (1.89 ± 0.37), (5.95 ± 0.78), (0.75 ± 0.22) and (4.56 ± 0.46) mmol / L, respectively (all P <0.05). After treatment, the differences between the two groups were statistically significant (P <0.05). The total effective rate of electrocardiogram in treatment group was 88.89%, which was significantly higher than that of control group (72.84%), the difference was statistically significant (P <0.05). The total effective rate of the treatment group was 92.59%, which was higher than 76.54% of the control group, the difference was statistically significant (P <0.05). Conclusion Tongxinluo capsule combined with atorvastatin calcium tablets in the treatment of coronary heart disease with hyperlipidemia clinical effect is worthy of clinical promotion.